Search
Tvardi Therapeutics Ord Shs
TVRDAdd to Watchlist
1.410USD
+0.452+47.18%
Close 11-09 16:00（ET）
18.81MMarket Cap
0.21P/E TTM
After-hours 19:35 (ET)1.580USD+0.240+17.91%
After-hours 19:35 (ET)Tvardi Therapeutics Ord Shs (TVRD) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts
Buy
2 Strong Buy
6 Buy
1 Hold
1 Sell
0 Strong Sell
Target Price
9.571USD+1107.29%
TVRD Analyst Recommendation Trends
In the current month, TVRD has received 6 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. TVRD average Analyst price target in the last month is 9.571.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
2
2
2
2
6
5
5
3
2
2
2
2
1
1
1
3
3
3
4
4
0
0
0
0
0
0
0
0
1
1
1
1
1
1
0
0
10
9
9
9
8
8
8
8
TVRD Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Biontech SE
BNTX
4
12
6
0
0
22
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Financial Forecasting
Based on analysts' estimates, TVRD EPS is projected to reach -0.546 in FY2026Q3, following reported EPS of -0.688 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.65
-0.74
-0.70
-0.55
-0.41
Actual
-0.77
-0.73
-0.69
--
--
Surprise
-19.73%
+2.56%
+2.23%
--
--
FAQs
What is Tvardi Therapeutics Ord Shs's price target?
Analysts forecast that Tvardi Therapeutics Ord Shs's price target is USD 9.57, with the highest forecast at USD 14.00 and the lowest forecast at USD 3.00.
How have Tvardi Therapeutics Ord ShsTVRD's recent earnings per share performed?
The market expectation was USD -0.69, while Tvardi Therapeutics Ord ShsTVRD's earnings per share (EPS) for the previous quarter was USD -0.73. EPS for the next quarter is expected at USD -0.55.
What is the analyst rating for Tvardi Therapeutics Ord Shs?
Based on the ratings of Tvardi Therapeutics Ord Shs's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.